William Owen Pickrell

William Owen Pickrell

Auto-generated profile, based on publicly available information

William Owen Pickrell

Swansea University

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
YFYen-Chen Anne Feng
Yen-Chen Anne Feng
DHDaniel P. Howrigan
Daniel P. Howrigan
LALiam E. Abbott
Liam E. Abbott
KTKatherine Tashman
Katherine Tashman
FCFelecia Cerrato
Felecia Cerrato
BNBenjamin M. Neale
Benjamin M. Neale

1 August 2016 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
CMCandace T. Myers
Candace T. Myers
JMJacinta M. McMahon
Jacinta M. McMahon
ASAmy L. Schneider
Amy L. Schneider
SPSlavé Petrovski
Slavé Petrovski
AAAndrew S. Allen
Andrew S. Allen
HMHeather C. Mefford
Heather C. Mefford

1 February 2017 in The Lancet Neurology
Verified
Journal Article
Open access
AAAndrew S Allen
Andrew S Allen
SBSusannah T Bellows
Susannah T Bellows
SBSamuel F Berkovic
Samuel F Berkovic
JBJoshua Bridgers
Joshua Bridgers
RBRosemary Burgess
Rosemary Burgess
MWMelodie R Winawer
Melodie R Winawer
Despite progress in understanding the genetics of rare epilepsies, the more common epilepsies have proven less amenable to traditional gene-discovery analyses. We aimed to assess the contribution of ultra-rare genetic variation to common epilepsies. We did a case-control sequencing study with exome sequence data from unrelated individuals clinically evaluated for one of the two most common epilepsy syndromes: familial genetic generalised epilepsy, or familial or sporadic non-acquired focal epilepsy. Individuals of any age were recruited between Nov 26, 2007, and Aug 2, 2013, through the multicentre Epilepsy Phenome/Genome Project and Epi4K collaborations, and samples were sequenced at the Institute for Genomic Medicine (New York, USA) between Feb 6, 2013, and Aug 18, 2015. To identify epilepsy risk signals, we tested all protein-coding genes for an excess of ultra-rare genetic variation among the cases, compared with control samples with no known epilepsy or epilepsy comorbidity sequenced through unrelated studies. We separately compared the sequence data from 640 individuals with familial genetic generalised epilepsy and 525 individuals with familial non-acquired focal epilepsy to the same group of 3877 controls, and found significantly higher rates of ultra-rare deleterious variation in genes established as causative for dominant epilepsy disorders (familial genetic generalised epilepsy: odd ratio [OR] 2·3, 95% CI 1·7-3·2, p=9·1 × 10-8; familial non-acquired focal epilepsy 3·6, 2·7-4·9, p=1·1 × 10-17). Comparison of an additional cohort of 662 individuals with sporadic non-acquired focal epilepsy to controls did not identify study-wide significant signals. For the individuals with familial non-acquired focal epilepsy, we found that five known epilepsy genes ranked as the top five genes enriched for ultra-rare deleterious variation. After accounting for the control carrier rate, we estimate that these five genes contribute to the risk of epilepsy in approximately 8% of individuals with familial non-acquired focal epilepsy. Our analyses showed that no individual gene was significantly associated with familial genetic generalised epilepsy; however, known epilepsy genes had lower p values relative to the rest of the protein-coding genes (p=5·8 × 10-8) that were lower than expected from a random sampling of genes. We identified excess ultra-rare variation in known epilepsy genes, which establishes a clear connection between the genetics of common and rare, severe epilepsies, and shows that the variants responsible for epilepsy risk are exceptionally rare in the general population. Our results suggest that the emerging paradigm of targeting of treatments to the genetic cause in rare devastating epilepsies might also extend to a proportion of common epilepsies. These findings might allow clinicians to broadly explain the cause of these syndromes to patients, and lay the foundation for possible precision treatments in the future. National Institute of Neurological Disorders and Stroke (NINDS), and Epilepsy Research UK.

23 February 2021 in Neurology
Verified
Journal Article
Open access
PDF file
LMLatif Miah
Latif Miah
HSHuw Strafford
Huw Strafford
BFBeata Fonferko-Shadrach
Beata Fonferko-Shadrach
JHJoe Hollinghurst
Joe Hollinghurst
ISInder M.S. Sawhney
Inder M.S. Sawhney
WPWilliam O. Pickrell
William O. Pickrell
Objective To characterize trends in incidence, prevalence, and health care outcomes in the idiopathic intracranial hypertension (IIH) population in Wales using routinely collected health care data. Methods We used and validated primary and secondary care IIH diagnosis codes within the Secure Anonymised Information Linkage databank to ascertain IIH cases and controls in a retrospective cohort study between 2003 and 2017. We recorded body mass index (BMI), deprivation quintile, CSF diversion surgery, and unscheduled hospital admissions in case and control cohorts. Results We analyzed 35 million patient-years of data. There were 1,765 cases of IIH in 2017 (85% female). The prevalence and incidence of IIH in 2017 was 76/100,000 and 7.8/100,000/y, a significant increase from 2003 (corresponding figures = 12/100,000 and 2.3/100,000/y) (p < 0.001). IIH prevalence is associated with increasing BMI and increasing deprivation. The odds ratio for developing IIH in the least deprived quintile compared to the most deprived quintile, adjusted for sex and BMI, was 0.65 (95% confidence interval 0.55 to 0.76). Nine percent of IIH cases had CSF shunts with less than 0.2% having bariatric surgery. Unscheduled hospital admissions were higher in the IIH cohort compared to controls (rate ratio 5.28, p < 0.001) and in individuals with IIH and CSF shunts compared to those without shunts (rate ratio 2.02, p < 0.01). Conclusions IIH incidence and prevalence is increasing considerably, corresponding to population increases in BMI, and is associated with increased deprivation. This has important implications for health care professionals and policy makers given the comorbidities, complications, and increased health care utilization associated with IIH.

18 December 2014 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
DSDarshan Sudarshi
Darshan Sudarshi
SLSarah Lawrence
Sarah Lawrence
WPWilliam Owen Pickrell
William Owen Pickrell
VEVinay Eligar
Vinay Eligar
RWRichard Walters
Richard Walters
MBMichael Brown
Michael Brown

1 September 2015 in EBioMedicine
Verified
Journal Article
Open access
CLCostin Leu
Costin Leu
SBSimona Balestrini
Simona Balestrini
BMBridget Maher
Bridget Maher
LHLaura Hernández-Hernández
Laura Hernández-Hernández
PGPadhraig Gormley
Padhraig Gormley
SSSanjay M. Sisodiya
Sanjay M. Sisodiya
Sudden unexpected death in epilepsy (SUDEP) represents the most severe degree of the spectrum of epilepsy severity and is the commonest cause of epilepsy-related premature mortality. The precise pathophysiology and the genetic architecture of SUDEP remain elusive. Aiming to elucidate the genetic basis of SUDEP, we analysed rare, protein-changing variants from whole-exome sequences of 18 people who died of SUDEP, 87 living people with epilepsy and 1479 non-epilepsy disease controls. Association analysis revealed a significantly increased genome-wide polygenic burden per individual in the SUDEP cohort when compared to epilepsy (P = 5.7 × 10(- 3)) and non-epilepsy disease controls (P = 1.2 × 10(- 3)). The polygenic burden was driven both by the number of variants per individual, and over-representation of variants likely to be deleterious in the SUDEP cohort. As determined by this study, more than a thousand genes contribute to the observed polygenic burden within the framework of this study. Subsequent gene-based association analysis revealed five possible candidate genes significantly associated with SUDEP or epilepsy, but no one single gene emerges as common to the SUDEP cases. Our findings provide further evidence for a genetic susceptibility to SUDEP, and suggest an extensive polygenic contribution to SUDEP causation. Thus, an overall increased burden of deleterious variants in a highly polygenic background might be important in rendering a given individual more susceptible to SUDEP. Our findings suggest that exome sequencing in people with epilepsy might eventually contribute to generating SUDEP risk estimates, promoting stratified medicine in epilepsy, with the eventual aim of reducing an individual patient's risk of SUDEP.